Oncolytic virus platform to treat hematological cancer
AssigneeArizona Board of Regents on behalf of Arizona State University
InventorsDouglas Grant Mcfadden, Lino Torres-Dominguez, Nancy Villa, Mohammed Masmudur Rahman
Life of this patent
Estimating the term…
Abstract
The disclosure provides Myxoma virus that expresses one or more immunomodulatory transgenes and its use in inhibiting and/or treating a hematological cancer in a subject. The disclosure also provides a leukocyte having a Myxoma virus that expresses one or more immunomodulatory transgenes and the use of the leukocyte for inhibiting and/or treating a hematological cancer in a subject.
Claims12
A myxoma virus (MXYV) comprising one or more immunomodulatory transgenes, wherein the one or more immunomodulatory transgenes encode a BiKE (Bi-specific Natural Killer and Neutrophil engager), wherein the BiKE comprises a first single chain variable fragment (scFv) that binds to CD16 and a second scFv that binds to a cancer-specific cell surface marker, wherein the cancer-specific cell surface marker is CD138, wherein the BiKE comprises SEQ ID NO:6.
Dependencies are inferred from the claim text.